Hosted on MSN15d
What to Know About CDK4/6 Inhibitors as Breast Cancer Treatment: Weighing the Risks vs. BenefitsAmong the many promising advances in breast cancer treatment in recent years are CDK4/6 inhibitors. These are targeted drugs that can be used for women with a common type of breast cancer ...
Clinical Trials Arena on MSN22d
AstraZeneca reports positive outcomes from breast cancer combo therapy trialAstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor as first-line ...
Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.
New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.
Gene expression testing helps determine chemotherapy needs for hormone receptor-positive breast cancer, optimizing treatment ...
While the global CDK4/6 inhibitor market remains highly competitive, VERZENIO's distinct clinical advantages and ongoing studies could contribute to further market expansion. VERZENIO (abemaciclib ...
Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and ...
Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback